Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,300 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,700 · Balance 44,300 F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2036-06-10 | Direct | 16,900 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Grant · Acquired 16,900 · Balance 16,900 F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 8,553 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,553 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 20:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 16,900 | $0.00 Strike: $23.30 | $0.00 |
DisclosureSEC source: 0001792164-26-000006 · wk-form4_1781296071.xml · derivative · entry 3 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,900 Underlying: Stock Option (Rights to Buy) · 16,900 shares Expires 2036-06-10 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 5,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001792164-26-000006 · wk-form4_1781296071.xml · nonDerivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,300 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| December 16, 2025 Filed May 12, 2026 20:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GiftCommon Stock | 5,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001792164-26-000003 · wk-form4_1778616552.xml · nonDerivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,600 F1 · shares: Gift to family members for estate planning purposes. F2 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 38,300 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001724521-25-000089 · wk-form4_1749760105.xml · derivative · entry 3 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 38,300 shares Expires 2035-06-09 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-25-000089 · wk-form4_1749760105.xml · nonDerivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,650 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $13.33 | $0.00 |
DisclosureSEC source: 0001724521-25-000019 · wk-form4_1738013435.xml · derivative · entry 3 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-01-22 F1 · derivative.exercise_date: The option is exercisable in 24 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 22:20 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001724521-24-000111 · wk-form4_1717798800.xml · derivative · entry 3 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-06-05 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 22:20 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000111 · wk-form4_1717798800.xml · nonDerivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,350 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:06 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $19.60 | $0.00 |
DisclosureSEC source: 0001209191-23-038144 · doc4.xml · derivative · entry 3 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2033-06-14 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:06 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 6,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038144 · doc4.xml · nonDerivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,950 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 16,800 | $0.00 Strike: $20.62 | $0.00 |
DisclosureSEC source: 0001209191-22-037443 · doc4.xml · derivative · entry 3 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,800 Underlying: Common Stock · 16,800 shares Expires 2032-06-13 F3 · derivative.exercise_date: The option will vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 4,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037443 · doc4.xml · nonDerivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,150 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. F2 · balance_after: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2022. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:44 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-21-038639 · doc4.xml · derivative · entry 3 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2031-06-02 F3 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:44 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038639 · doc4.xml · nonDerivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,050 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. F2 · balance_after: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2021. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:34 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $30.05 | $0.00 |
DisclosureSEC source: 0001209191-20-034991 · doc4.xml · derivative · entry 3 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:34 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034991 · doc4.xml · nonDerivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,050 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 4, 2021 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 15:52 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0001209191-20-004403 · doc4.xml · derivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-12-31 F1 · shares: Award made to members of Arcus's Scientific Advisory Board. F2 · derivative.exercise_date: The option is exercisable in 24 equal monthly installments after January 1, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 20:04 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to buy) · Derivative | 50,000 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0001209191-19-054500 · doc4.xml · derivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock · 50,000 shares Expires 2029-10-27 F1 · derivative.exercise_date: The option is exercisable in 36 equal monthly installments after October 28, 2019, subject to the Reporting Person's continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.